MIRA Pharmaceuticals (NASDAQ:MIRA) Announces Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) posted its quarterly earnings results on Friday. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14, Zacks reports.

MIRA Pharmaceuticals Stock Down 3.6 %

NASDAQ:MIRA traded down $0.04 during trading hours on Friday, hitting $1.06. 82,074 shares of the company’s stock traded hands, compared to its average volume of 1,917,130. The firm has a market cap of $17.55 million, a P/E ratio of -1.89 and a beta of 2.31. The business’s fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $1.23. MIRA Pharmaceuticals has a 52 week low of $0.51 and a 52 week high of $5.01.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.